These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16462708)

  • 1. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis.
    Mangiagli A; Campisi S; De Sanctis V; Nicoletti MC; Cardinale G; Galati MC; Raiola G; Rigano P; Saviano A;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():276-8. PubMed ID: 16462708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism.
    Mangiagli A; Campisi S; De Sanctis V; Nicoletti MC; Cardinale G; Galati MC; Raiola G; Rigano P; Saviano A;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():272-5. PubMed ID: 16462710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
    Nishimura R
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
    Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance.
    Shinoda Y; Inoue I; Nakano T; Seo M; Sassa M; Goto S; Awata T; Komoda T; Katayama S
    Metabolism; 2006 Jul; 55(7):935-9. PubMed ID: 16784967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
    Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
    Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The continuous glucose monitoring system (CGMS) in patients with beta-thalassemia major and impaired glucose homeostasis: preliminary results.
    Rimondi F; Banin P; Gamberini MR; De Sanctis V
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():190-2. PubMed ID: 19337177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
    Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
    J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Insulin sensitivity and beta cell function in different glucose tolerance status].
    Gómez-García A; Magaña-Garns P; Ruiz-García J; Alvarez-Aguilar C
    Invest Clin; 2006 Jun; 47(2):155-66. PubMed ID: 16886777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
    Gamberini MR; Fortini M; De Sanctis V; Gilli G; Testa MR
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():285-91. PubMed ID: 16462713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
    Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.